paediatrics Brussels 17

SIOP WT 2001 Pritchard-Jones et al SIOP Abstract 2011 Pediatric Blood and Cancer 57 (5), 741, 2011

• Can doxorubicin be safely omitted from chemotherapy for stage II/III, intermediate risk WT? • SIOP multicentre trial (28 countries, 261 centres) • 4 weeks pre-op VCR /ActD, delayed nephrectomy • Stage II/III intermediate risk WTs were randomized between 26 weeks AV or AVD (total Doxo 250 mg/m2) • Stage III tumours received 14.4 Gy flank RT